PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Phenotype | C0018801|heart failure |
| Sentences | 11 |
| PubMedID- 22687841 | We present the case of a 42-year-old japanese woman who developed acute heart failure after chemotherapy with epirubicin for breast cancer. |
| PubMedID- 23975515 | The wide use of anti-her2/erbb2 therapies (trastuzumab, lapatinib, pertuzumab) in oncology resulted in a huge increase of iatrogenic cardiac dysfunction or heart failure in patients with breast cancer. |
| PubMedID- 22949432 | Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. |
| PubMedID- 25342090 | Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin. |
| PubMedID- 21301318 | It is very important to reduce the risk of cardiovascular complications, especially heart failure, in breast cancer survivors. |
| PubMedID- 25096848 | Background and objective: congestive heart failure (chf) risk with bevacizumab in breast cancer has been previously investigated in a meta-analysis, but its incidence and the risk of chf in other tumor types remain unclear. |
| PubMedID- 21205755 | Congestive heart failure risk in patients with breast cancer treated with bevacizumab. |
| PubMedID- 23425978 | Background: chemotherapy with trastuzumab and anthracycline is associated with incident heart failure (hf) in patients with breast cancer. |
| PubMedID- 21205751 | Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side. |
| PubMedID- 23141499 | Objectives: the aim of this study was to evaluate the effect of continuous statin treatment on new-onset heart failure (hf) in patients with breast cancer receiving anthracycline-based chemotherapy. |
| PubMedID- 25038879 | Cardiac glycosides and the risk of breast cancer in women with chronic heart failure and supraventricular arrhythmia. |
Page: 1